Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indivior PharmaceuticalsINDV +0.36%81 EBITDA Margin % is 48.10% as of Jun. 2026, which is 202% above its 10-year median of 15.93. GuruFocus rates INDV with a GF Score™ of 81/100 and a GF Value™ of $24.23 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 88.74% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Indivior Pharmaceuticals EBITDA Margin % Related Terms
Indivior Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INDV vs KNSA, AMRX, HIMS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals (INDV) has a EBITDA Margin % of 48.10% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indivior Pharmaceuticals and its competitors. This is 202% above median its historical median of 15.93. According to the industry distribution chart, Indivior Pharmaceuticals ranks #108 out of 959 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Indivior Pharmaceuticals' EBITDA Margin % too high?
Indivior Pharmaceuticals' current EBITDA Margin % of 48.10% is 202% above median its 10-year median of 15.93. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Indivior Pharmaceuticals' value of 48.10% is 297.2% above this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #108 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' EBITDA Margin % compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #108 out of 959 companies for EBITDA Margin %. This places Indivior Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.11. Indivior Pharmaceuticals' value of 48.10% is 297.2% above this benchmark. While the company's 10-year median is 15.93 vs. the industry median of 12.11, Indivior Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current EBITDA Margin % of 48.10% is 297.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current EBITDA Margin % is 48.10%, which is 202% above median its own 10-year median of 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.23, compared to a current price of $38.83 — trading 60.3% above its estimated fair value. The current EBITDA Margin % is 48.10%, which is 202% above median its 10-year median of 15.93 and 297.2% above the Drug Manufacturers industry median of 12.11. Indivior Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current EBITDA Margin % is 48.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $38.83 is trading 60.3% above its estimated GF Value™ of $24.23.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
EBITDA Margin %: 48.10% (202% above median its 10-year median of 15.93)
GF Value™: $24.23 vs. price of $38.83 (60.3% above fair value)
Industry Position: 297.2% above the Drug Manufacturers median (#108 of 959)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
81GF Score
Get the complete analysis for INDV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
